Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
About this item
Full title
Author / Creator
Dunn, Lara A , Sherman, Eric J , Baxi, Shrujal S , Tchekmedyian, Vatche , Grewal, Ravinder K , Larson, Steven M , Pentlow, Keith S , Haque, Sofia , Tuttle, R Michael , Sabra, Mona M , Fish, Stephanie , Boucai, Laura , Walters, Jamie , Ghossein, Ronald A , Seshan, Venkatraman E , Ni, Ai , Li, Duan , Knauf, Jeffrey A , Pfister, David G , Fagin, James A and Ho, Alan L
Publisher
Washington, DC: Endocrine Society
Journal title
Language
English
Formats
Publication information
Publisher
Washington, DC: Endocrine Society
Subjects
More information
Scope and Contents
Contents
Abstract
Context
BRAFV600E mutant thyroid cancers are often refractory to radioiodine (RAI).
Objectives
To investigate the utility and molecular underpinnings of enhancing lesional iodide uptake with the BRAF inhibitor vemurafenib in patients with RAI-refractory (RAIR).
Design
This was a pilot trial that enrolled from June 2014 to...
Alternative Titles
Full title
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
Authors, Artists and Contributors
Author / Creator
Sherman, Eric J
Baxi, Shrujal S
Tchekmedyian, Vatche
Grewal, Ravinder K
Larson, Steven M
Pentlow, Keith S
Haque, Sofia
Tuttle, R Michael
Sabra, Mona M
Fish, Stephanie
Boucai, Laura
Walters, Jamie
Ghossein, Ronald A
Seshan, Venkatraman E
Ni, Ai
Li, Duan
Knauf, Jeffrey A
Pfister, David G
Fagin, James A
Ho, Alan L
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6435099
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6435099
Other Identifiers
ISSN
0021-972X
E-ISSN
1945-7197
DOI
10.1210/jc.2018-01478
